Alumis Announces $259M Series C Financing

South San Francisco, CA, March 6, 2024 (VC News Daily) -- Alumis Inc., a pioneering clinical-stage biopharmaceutical enterprise dedicated to revolutionizing patient care in immune-mediated diseases through precision oral therapies, has disclosed an expanded Series C financing totaling $259M. This funding round, spearheaded by Foresite Capital alongside fresh investors Samsara BioCapital and venBio Partners, showcases robust confidence in Alumis' innovative approach.

Read full article here.